Optimization of an immunotherapeutic protocol with poly(I,C)-LC

James E. Talmadge, Diethelm Hartmann

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

The development of successful immunotherapeutic protocols requires new therapeutic strategies as well as the development of clinically predictive tumor models and protocols. A bell-shaped response curve is observed with many biological response modifiers (BRMs), not only for immunomodulation, but also for therapeutic activity. Although most BRMs, including poly(I,C)-LC, are toxic at high doses, the administration of nontoxic doses by an optimal protocol and route of injection results in significant therapeutic benefit and increased immunodulation in tumor-bearing animals compared to the administration of a maximum tolerated dose (MTD). We suggest that Phase II clinical trials using an optimal immunomodulatory protocol may result in increased therapeutic activity compared to protocols based on the MTD.

Original languageEnglish (US)
Pages (from-to)484-489
Number of pages6
JournalJournal of Biological Response Modifiers
Volume4
Issue number5
StatePublished - Oct 1985

    Fingerprint

Keywords

  • Immunotherapy
  • Metastasis
  • Poly(I,C)-LC

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Cancer Research

Cite this